Skip to content Skip to footer
VIEWPOINTS_Steffen-Sebastian Bolz_2023

Steffen-Sebastian Bolz, CSO of Aphaia Pharma Shares Insights from the P-II Study for Chronic Weight Management in Individuals with Obesity

Shots:  Steffen shared the details of the first patient enrolled in the P-II study of Aphaia Pharma’s lead product APH-012 to induce weight loss in individuals with obesity  He briefed the PharmaShots team about the study design of the P-II trial and also elaborated on the results from the P-I study The interview shows how…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]